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In 1990, the UK Parliament voted in favour of a Bill to allow
the generation and use of human embryos in vitro, including
their regulated use in research and assisted reproduction
(HFE Act, 1990). Mulkay (1997), in his influential account
of the late 1980s debates leading to the passage of this Act,ter ª 2011, Reproductive Healthcare Ltd.
.008attributes a key role to preimplantation genetic diagnosis
(PGD) in shaping the form of this legislation (pp. 132–133).
He claims that supporters of embryo research convinced
MPs that ‘many forms of genetic disorder could be more
or less eradicated by means of genetic screening of IVF
embryos’ (p. 41). Indeed, just 5 days before the 1990 Com-
mons vote, a team from the Hammersmith Hospital led byPublished by Elsevier Ltd. All rights reserved.
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lowing use of PGD to avoid transmission of a sex-linked
genetic disease (Handyside et al., 1990). Winston himself
suggested ‘parliamentary opinion had been decisively
altered. . . by this clear demonstration that research on
human embryos really does produce genuine therapeutic
benefits’ (cited in Mulkay, p. 42). Likewise, Franklin and
Roberts (2006, p. 39), in their ethnography of PGD in the
UK, confirm the ‘decisive role’ of the technique-in-the-
making that was ‘hailed as ‘‘winning the vote’’’ by ‘focusing
and clarifying public attitudes’. They describe the powerful
‘bridging capacity’ of PGD between ‘the promise of almost
immediate future benefit’ and the need for ‘considerable
ongoing scientific research’ at the time (p. 58).
This paper traces the early history of PGD from demon-
stration in principle in animal studies in 1968 to clinical
application in 1990, and asks the question: what influenced
its development as a medical technology? Research shows
that not only did innovations in medical technology shape
Parliamentary decisions, but that the political debate itself
exerted a critical motivational stimulus to achieve PGD
clinically.
Materials and methods
Sources
The Hansard database, containing verbatim records of UK
Parliamentary debates, was used to explore the role of
PGD in the embryo research debate from the discussions
of the Warnock Report (Warnock, 1984) to those of the
HFE Bill in 1990. These debates are cited by speaker and
year in the text (e.g. Lord Ennals: Hansard, 1990), and by
a complete online database reference in the reference list.
Archival material was accessed from the UK Medical
Research Council (MRC) records at the National Archives
at Kew, Surrey, UK (NA); from the papers of Professor Peter
Braude and the Progress Educational Trust papers held at
the London School of Economics’ Archive (LSE); from the
Anne McLaren papers at the British Library (BL); and from
Enoch Powell’s personal papers in the Churchill College
Archives, Cambridge (CC). These archival sources comprise
folders or boxes, each containing up to several hundred
unnumbered items. These sources are cited with a num-
bered archival code in the order that they appear in the text
(NA1–5; LSE1–14; BL1–3 and CC1–10) and are included in a
separate archival reference list as a short description, date
and archival location by box/folder division and subdivision,
where applicable.
This study also draws on information from unpublished
interviews by Professors Martin Johnson and Sarah Franklin
with: Dame Mary Warnock, Chair of the Committee of
Enquiry into Human Fertilisation and Embryology from
1982–1984; Mrs Jenny C Croft, the secretary to the Commit-
tee; and Roy Cunningham, Assistant Secretary at the
Department of Health.
Historical nomenclature
Preimplantation genetic diagnosis (PGD) now refers to the
clinical technique of diagnosing genetic characteristics inpreimplantation embryos without precluding viability or
further embryonic and fetal development following transfer
to a receptive uterus. Before being applied clinically in
1990, several different names were used to describe the
concept underlying this technique. For example, initial
animal studies referred mainly to ‘embryo sexing’ (Hare
and Betteridge, 1978). The terms ‘preimplantation diagno-
sis’ (McLaren, 1985), ‘preimplantation genetic diagnosis’
(Penketh and McLaren, 1987) and ‘embryo biopsy’ (CC1)
all appeared in the literature between 1985 and 1990, along
with ‘prenatal diagnosis before implantation’ (McLaren,
1985) and ‘preimplantation genetic screening’ (Whitting-
ham and Penketh, 1987). It is unclear when the acronyms
PID, PGD and PIGD were first introduced, although a PubMed
search did not reveal their published use before 1993 (PID;
Holding et al., 1993), 1994 (PGD; Verlinsky and Kuliev, 1994)
and 1997 (PIGD; Davis, 1997). However, as PubMed searches
return only hits from the title and abstract (where avail-
able) and do not include other sources such as newspaper
articles, it is possible that these acronyms were used
earlier. Harper (2009, p. 5) suggests that the concept was
referred to as ‘preimplantation diagnosis’ or ‘PID’ in many
of the first papers, but that the name ‘was changed’ to
PGD ‘by people entering the field later on to avoid confusing
the acronym PID with that for pelvic inflammatory disease’.
Criteria for the PGD concept
Since the underlying concept of PGD went by several differ-
ent names before 1990 and appeared in a variety of con-
texts, a source was considered to be pertinent to PGD if it
demonstrated one or both of two criteria: (i) a desire or
intent to diagnose preimplantation embryos without pre-
cluding further development or transfer, even if the meth-
ods or results were not compatible with these aims (e.g.
studies on gametes or on whole embryos but with reference
to the possibility of embryo biopsy); and (ii) methods or
results describing diagnosis without precluding further
development or transfer, even if the desire or intent for
embryo transfer was absent (e.g. sexing embryo biopsies
to study X-inactivation and gene dosage, rather than for
commercial or clinical diagnostic incentives).
Results
Technological development
The earliest reference to the concept of PGD dates to 1965
and to Robert Edwards (1965), who was to achieve IVF in
humans in 1969 and led to the birth of Louise Brown in 1978
(Johnson et al., 2010). In 1967, the concept of PGD was
fleshed out experimentally in an attempt to sex in-vivo gener-
ated rabbit blastocysts, by using euchrysine vital staining and
fluorescence microscopy to visualize sex chromatin (a
nuclear inclusion of the condensed and inactive X chromo-
some, indicating female sex; Edwards and Gardner (1967)).
However, this technique, involving the exposure of thewhole
embryo to fluorescent light, was potentially mutagenic and
not safely compatible with embryo transfer. The following
year, Gardner and Edwards (1968) micro-surgically biopsied
200–300 trophoblast cells, stained and examined them and
Table 1 Comparison of the first experimental and clinical demonstrations of PGD.
Comparison First experimental demonstration
(Gardner and Edwards, 1968)
First clinical application
(Handyside et al., 1990)
Species Rabbit (2.5-mm diameter embryo) Human (150 mm diameter embryo)
Fertilization In vivo and recovery from uterus IVF
Embryo biopsy Trophoblast biopsy (200–300 cells) Single blastomere biopsy (1 cell)
Diagnosis Sex chromatin visualization Y chromosome-specific PCR
Embryo age Biopsied 5.75 days after fertilization Biopsied 3 days after fertilization
Embryos used 121 embryos from 15 rabbits 63 embryos from 112 eggs, 10 cycles with five
couples
Sexinga 119 (98%) embryos biopsied, 104 (86%)
embryos sexed
50 (79%) embryos biopsied, 46 (73%) embryos
sexed
Embryos
transferreda
40 (33%) embryos implanted, 24 fetuses at
term (20%)
17 embryos transferred (27%), two twin
pregnancies (6.3%)
Accuracy 18/18 offspring correctly sexed (confirmed
at full term)
4/4 fetuses correctly sexed (confirmed by CVS
at 10 weeks)
CVS = chorionic villus sampling.
aPercentage of fertilized embryos used.
History of PGD 459then transferred the ‘sexed’ biopsied blastocysts to pseudo-
pregnant recipients. The sex of the developed fetuses was
confirmed anatomically and histologically at full term, pro-
viding ‘a reliable method of sexing’ which was ‘compatible
with further development’. Theyalso addressed thepotential
for clinical application, stating that the ‘scope of experimen-
tal embryology could be greatly extended’ to include the
detection of ‘autosomally inherited deformities from either
parent’ (Anon, 1968; Edwards and Gardner, 1968; Gardner
and Edwards, 1968). Twenty-two years later, this pioneering
study was successfully translated to the clinic.
A conventional understanding is that technological
problems had to be solved for this translation to happen.
Thus, the human embryo is smaller and has fewer cells than
the rabbit embryo and its sex chromatin cannot be visual-
ized as easily, necessitating the use of more sensitive, reli-
able and discriminating diagnostic technologies (Table 1).
Indeed, Harper (2009, p. 4) suggests that the ‘challenge of
the introduction of molecular biology for PGD was the move
from working with millions of cells to the very few cells of
the embryo’. As late as 1985, it was ‘generally agreed that
therewereno single-cell diagnostic techniques available, and
that the biopsied cell(s) would have to be cultured to obtain
sufficient cells for the diagnosis’ (Harper, 2009, p. 3). In addi-
tion, it was considered ‘unlikely’ that diagnosis and transfer
could be achieved within the same menstrual cycle and that
clinical PGDwould thus ‘depend on the successful application
of embryo cryopreservation’ (West et al., 1987). Successful
freezing with subsequent thawing, transfer and clinical
pregnancy was described for animals by Whittingham et al.
(1972) and for humans by Trounson and Mohr (1983). In fact,
however, the first clinical application of PGD used fresh
embryos and employed the polymerase chain reaction (PCR)
to amplify DNA specific to the Y chromosome (Handyside
et al., 1990).
A second technical obstacle was the need for enough
human embryos to develop PGD technology. Animal
embryos – and with difficulty human embryos (Table 2) –
could be obtained by lavage of the uterus and oviductsin situ or by flushing removed organs. IVF provided an alter-
native source of embryos, although this was not demon-
strated convincingly in humans until 1969 (Edwards et al.,
1969) and the first IVF births not achieved until 1978
(Edwards and Steptoe, 1978). Moreover, although human
blastocysts were produced after IVF as early as 1971 (Step-
toe et al., 1971), their routine production was considered
too difficult, meaning that only cleavage-stage biopsy could
be contemplated thereby providing even fewer cells for
testing. Even by 1969, the generation of animal fetuses
and live young by IVF and embryo transfer was not routine,
having been achieved only in rabbits (Chang, 1959),
hamsters (Yanagimachi and Chang, 1963) and mice (Whit-
tingham, 1968). Thus, it has been argued that species differ-
ences between human and rabbit embryos necessitated
technological developments and that the lack of research
embryos and appropriate diagnostic techniques impeded
successful research on the clinical application of PGD in
humans for 22 years.
The technological explanation evaluated
Undoubtedly technological limitations were problematic.
However, motivation was required to overcome these prob-
lems. What evidence of such motivation exists and when is
it first apparent?
Experience with preimplantation sexing in animals
In 1978, the control of the sex ratio in cattle and other farm
animals was described as an alluring ‘old dream’ (cited in
Hare and Betteridge, 1978), due to the potential commer-
cial advantages of selectively producing dairy cattle and
tender beef and preventing the occurrence in multiple
pregnancies of free martins (female fetuses partially mascu-
linized by exposure to adjacent male fetuses; Winterber-
ger-Torres and Popescu, 1980). Pre-fertilization sperm
sexing had been described as the ‘ideal method of control-
ling the sex ratio’ in cattle and was pursued through the
1970s and 1980s by investigating whether X- and Y-bearing
Table 2 Time line of sources of human eggs and embryos.
Author(s) year Method Patients Eggs/embryos
Rock and Menkin
(1944)
Laparotomy + IVFa 3 18 eggs inseminated; 4/18 eggs 2
cellsa
Rock and Hertig
(1948)
Hysterectomy 122 26 embryos
Hertig et al. (1959) Hysterectomy 210 34 embryos
Edwards (1965) Ovarian biopsy 16 250 unfertilized eggs
Edwards et al.
(1969)
Ovarian biopsy + IVF NA 56 eggs inseminated; 7/56 eggs 2
pronuclei
Edwards et al.
(1970)
Laparoscopy + IVF 49 212 eggs inseminated; 38/212 eggs 2
cells
Clewe et al. (1971) Hysterectomy 9 9 eggs collected; 1/9 eggs 2 pronuclei
Croxatto et al.
(1972)
Uterine lavage 42 5 unfertilized eggs and 3 embryos
Lopata et al. (1974) Laparoscopy or laparotomy 70 217 unfertilized eggs
Buster et al. (1983) Donor uterine lavage + transfer to
recipient
14 5 eggs and 5 embryos; 2 pregnancies
Buster et al. (1985) Donor uterine lavage + transfer to
recipient
5 25 embryos; 3 pregnancies
Formigli et al. (1987) Donor uterine lavage + transfer to
recipient
42 23 embryos; 8 pregnancies
Formigli et al. (1990) Donor uterine lavage + transfer to
recipient
127 48 embryos; 18 pregnancies
NA = not applicable.
aIVF claimed but subsequently disputed.
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volume, charge or motility, but these approaches were
largely unsuccessful (Van Vliet et al., 1989). Indeed, sexing
of preimplantation embryos was singled out as seeming
‘more encouraging’ agriculturally (Hare and Betteridge,
1978) and a number of experimental studies were reported
in the 1970s and early 1980s.
Following the 1968 rabbit study, the next reports on the
PGD principle were in sheep (cited in Polge and Rowson,
1975) and cattle (Hare et al., 1976), both of which produce
large preimplantation embryos with many trophoblast cells.
Trophoblast biopsies were sexed from metaphase spreads
and the diagnosis confirmed by embryo transfer. Hare
et al. (1976) reported confident sexing of 20/34 biopsied
embryos (58.8%) but could not sex 11 due to absent or poor
metaphase spreads. Sex was confirmed correctly following
birth, slaughter or spontaneous abortion in 7/8 cases. Two
later studies also used metaphase spreads on fewer cells
biopsied from earlier embryos. Moustafa et al. (1978) biop-
sied only 7–10 blastomeres per bovine embryo, and deter-
mined sex successfully in 63% of 29 day-6 morulae and 53%
of 15 day-7 early blastocysts. The authors reported ‘no del-
eterious effect on the subsequent embryonic and fetal
developments’ following biopsy and transfer to a recipient
uterus. In 1983, Severova and Dyban claimed successful sex-
ing in mice by isolating and culturing a single blastomere at
the 4-cell stage, the remaining three cells developing into a
normal blastocyst. Both these later studies suggested an
application in farm animals, and, crucially, both demon-
strated approaches to PGD that required neither PCR nor
hundreds of cells, unlike the methods of Handyside et al.
(1990) and of Gardner and Edwards (1968), respectively.However, none of these four accounts referred to the possi-
bility of pursuing PGD clinically in humans, nor of its use to
avoid genetic disease. In contrast, Modlinski and McLaren
(1980), using polar body karyotyping in an attempt to assess
the status of the maternal chromosomal complement in the
embryo, did refer to the possibility of clinical PGD, but were
pessimistic about its likely usefulness.
Embryo typing by enzyme micro-assay was described by
Epstein et al. (1978), who separated mouse blastomeres at
the 2-cell stage and cultured each to give ‘twin half-embryos’.
One of these halves was sexed by assaying for the X-linked
enzyme hypoxanthine-guanine phosphoribosyltransferase
(HPRT) and the other by karyotyping. Although this sensitive
enzyme assay, used in combination with ‘embryo biopsy by
splitting’, demonstrated the feasibility of PGD in the absence
of PCR, the authors made no reference to the principle of PGD
or to transferring an untested ‘half-embryo’, butwere focused
on understanding the processes of X inactivation and gene dos-
age in preimplantation embryos. Around the same time, Monk
and her colleagues increased the sensitivity of her enzyme
micro-assays sufficient to type single cells, but did not use
them for that purpose or mention PGD (Monk and Kathuria,
1977; Monk and Harper, 1978, 1979).
An immunological approach to mouse embryo sexing was
reported by Krco and Goldberg (1976), who showed that
exposure of embryos to an antiserum to the male histo-
compatibility-Y antigen resulted in lysis ofmale preimplanta-
tion embryos, leaving only female embryos. However, like
Epstein et al. (1978), the authors did not suggest a clinical
or commercial application for theirmethod. This immunolog-
ical approach was later applied to bovine embryos with a
reported accuracy of 80–93% (cited in Beardsley, 1983;
History of PGD 461Shapley, 1983). Indeed, a patent for this method was filed in
1983 in America, providing an early example of the commer-
cial use of sexing (Hare and Betteridge, 1983; Shapley, 1983).
These animal studies in the 1970s and early 1980s showed
that PGD could be achieved in the absence of PCR, or even
single cell biopsy and testing, although the accuracy and
feasibility of these approaches was not tested on a large
scale. However, only Modlinski and McLaren (1980) referred
to its possible use in humans for either sexing or diagnosing
other genetic characteristics or diseases, a theme also
picked up in a news item in Nature entitled ‘Cattle now,
people next?’ (Beardsley, 1983), in which Edwards was cited
as finding the results of cattle sexing experiments
‘extremely interesting’. Otherwise, the possible human
application of PGD was ignored and was not seriously
engaged with again until 1986.
Pursuing PGD in human embryos
Whilst it is true that human embryos were hard to come by
in the 1960s and 1970s (Table 2), Edwards and Steptoe
made rapid progress in their culture of IVF embryos
(Edwards and Steptoe, 1974; Edwards et al., 1970; Steptoe
et al., 1971). So encouraging were the outcomes obtained
by Edwards and Steptoe that they approached the MRC in
1970 for long-term support and formally submitted a grant
application in February 1971 (Johnson et al., 2010). It is
clear that Edwards and Steptoe believed that PGD was ame-
nable to study and that adequate numbers of embryos could
be generated for this purpose. Edwards (1971) suggested
that the ‘next development’ in IVF studies ‘could well be
the sexing of embryos before transfer and that this would
be ‘an excellent approach to the control of sex-linked
mutant genes in man’, and they included PGD in their grant
proposal as one of two core objectives (NA1):
The basic research is helping our understanding of
various aspects of human reproduction. Clinical
application of the findings could lead to the alleviation
of infertility in some cases, and might eventually provide
the means for averting the birth of children with certain
inherited disorders.
These aims were reiterated in a working party report of
the British Association for the Advancement of Science
(Jones and Bodmer, 1974, p. 31), of which Edwards was a
member. In addition, a 1972 study by the British Medical
Association reported on the potential to ‘diagnose certain
fetal abnormalities in fertilized ova’ and that ‘this way
might be preferable to termination at 16 weeks’ following
amniocentesis (cited in Jones and Bodmer, 1974, pp.
120–121). Pembrey (1979), stimulated by a paper from
Craft and Yovich (1979), addressed this question obliquely
by proposing the use of embryo donation as a way of avoid-
ing transmission of genetic disease. Moreover, sex selection
by sperm sorting had also been tried unsuccessfully in
humans, indicating interest in genetic selection (Schaffir,
1991). However, there was little enthusiasm for PGD itself.
Indeed, the MRC declined to fund Edwards and Steptoe’s
experiments (Johnson et al., 2010).
It was not until the mid-1980s that a clear motivation to
achieve clinical PGD emerged. Thus, late in 1986, twomeetings convened to discuss the prospects for achieving
PGD were held: one at the CIBA Foundation (13 November,
organized by David Whittingham and Richard Penketh) and
one at the European Society for Human Reproduction and
Embryology (ESHRE; 16 December in Strasbourg). These
meetings were attended by several prominent UK players
then pursuing human embryo research, many of whom
engaged later in research to achieve PGD clinically
(Table 3). The report on the CIBA Foundation meeting
(Whittingham and Penketh, 1987) reviewed technologies
for PGD and drew attention to both in-situ hybridization,
which had recently been used to diagnose trisomy 21 by
amniocentesis (Julien et al., 1986) and to PCR. The latter
was discussed by Marcus Pembry in his 10 min talk entitled
‘Molecular diagnosis – the potential for gene amplification’
(Christie and Tansey, 2003, p. 53), and, in handwritten
notes on the programme for this meeting, Anne McLaren
(BL1) recorded that a paper on this topic had been published
the same week in Nature (November 13–19; Saiki et al.,
1986). Edwards is reported by Pembrey as jumping up and
dancing around the room saying ‘75 cells, 75 cells, we are
going to be able to do it!’ because he had earlier said ‘I
don’t think it is on, we can’t give you geneticists enough
cells’. (Christie and Tansey, 2003, p. 53). The meeting sum-
mary concluded that there was a clear clinical need for PGD
and that research on human embryos was required to
achieve it (Whittingham and Penketh, 1987).
The ESHRE meeting was stimulated, chaired and opened
by Edwards (1987), who reviewed approaches to sex selec-
tion and PGD. At Edwards’ request, a potential diagnostic
role for PCR was presented (Southern, 1987) based on the
paper by Saiki et al. (1985; published 20 December) while
Jones et al. (1987) presented their preliminary results using
in-situ hybridization to sex human and mouse spermatozoa
and whole preimplantation embryos. It is clear from the
planning and proceedings of this meeting that Edwards
had been galvanized into renewed activity regarding PGD
(Brambati, 1987; Edwards and Hollands, 1988), including
an exhortation to fight political pressures to ban the
research that might make it possible (Anon, 1987).
Soon afterwards, the research pace increased. Non-
invasive approaches to PGD were investigated as less tech-
nically and ethically challenging alternatives to embryo
biopsy (Edwards, 1987), including measurement of pyruvate
turnover to assess viability of whole human embryos and
eggs (Hardy et al., 1989; Leese et al., 1986). PCR analysis
on human and mouse oocytes, sperm cells and whole
embryos indicated a practical route towards PGD (Coutelle
et al., 1989; Li et al., 1988). Different experimental biopsy
methods were investigated (Dokras et al., 1990; Summers
et al., 1988; Verlinsky et al., 1990; Wilton and Trounson,
1989). A mouse model for PGD was developed, using single
blastomere and trophoblast biopsies to sex embryos by
assaying for the X-linked enzyme HPRT (Monk, 1988; Monk
and Handyside, 1988; Monk et al., 1987, 1988). These exper-
iments built on previous work by Monk and co-workers (Monk
and Kathuria, 1977; Monk and Harper, 1978, 1979; Monk and
McLaren, 1981; McMahon et al., 1981, 1983; McLaren and
Monk, 1981; Harper and Monk, 1983), who, like Epstein
(1969, 1970, 1978) had used X-linked enzyme assays to study
dosage compensation and X inactivation in whole preim-
plantation mouse embryos, but, also like Epstein et al.
Table 3 Key players involved in human embryo research and/or discussion and research on human
preimplantation genetic diagnosis (PGD) who attended CIBA and/or European Society of Human Reproduc-
tion and Embryology (ESHRE) meetings in 1985–1986.
Name (location) CIBA meeting: embryo
research (11 June 1985)
CIBA meeting: PGD (13
November 1986)
ESHRE meeting: PGD (16
December 1986)
J Aitken
(Edinburgh)
+ – –
D Baird (Edinburgh) + – –
P Braude
(Cambridge)
+ – –
R Edwards
(Cambridge)
+ + +
A Handyside
(Carshalton)
– + –
M Johnson
(Cambridge)
+ + –
K Jones
(Edinburgh)
– – +
H Leese (York) – – +
M Macnaughton
(London)
– + –
J Maddox (Nature) + – –
A McLaren
(London)
+ + +
B Modell (London) + + +
M Monk (London) – + –
A Muggleton-Harris
(Carshalton)
– + –
R Penketh
(London)
– – +
M Pembry (London) – + –
D Whittingham
(Surrey)
– – +
B Williamson
(London)
+ – –
R Winston (London) – + –
+ = attended meeting.
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to type and transfer embryos for research, commercial or
clinical purposes. In striking contrast, Monk and her
colleagues clearly specified in their 1987 study the scope
for applying PGD clinically and followed it by developing
mouse models for adenosine deaminase deficiency and
b-thalassaemia (Benson and Monk, 1988; Holding and Monk,
1989). Sexing of human IVF embryos by micro-enzyme
assays (Braude et al., 1989), in-situ hybridization (Grifo
et al., 1990; West et al., 1987) and Y-chromosome PCR
(Handyside et al., 1989) were reported and pregnancy
resulting from transfer of PCR-sexed human embryos fol-
lowed (Handyside et al., 1990).
These human-oriented studies differed from the inter-
vening work in animals in three key respects. First, many
of them were published in journals with a wider inter-
disciplinary audience, such as Nature and The Lancet,
rather than in specialist agricultural journals such as
Theriogenology. Second, whilst studies and discussions onhuman PGD did emphasize the potential for sexing to avoid
X-linked genetic disease, they also expressed the hope that
PGD could soon be extended to detect further genetic con-
ditions. In contrast, earlier animal studies had focused
heavily on preimplantation sexing for commercial and
scientific reasons. Finally, these studies were clearly the
result of a concerted effort to achieve PGD clinically.
Conclusion
From 1986–1987 onwards, there was a quite sudden surge in
interest and activity in clinical PGD. Whilst technological
limitations undoubtedly posed difficulties from the late
1960s to the mid-1980s, after which possible solutions were
beginning to emerge, the collective motivation to engage
with PGD is not readily explicable in technological terms
alone. How can the previous lack of interest in achieving
clinical PGD be explained? And what had changed by
1986?
History of PGD 463The motivation to achieve clinical PGD
Two broad factors seem to underlie this sudden change of
motivation. First, changing attitudes to prenatal testing
and IVF introduced a climate more favourably disposed to
PGD. Second, political events in the UK that threatened sci-
entists’ capacity to undertake research on human embryos
provided a positive stimulus to actively pursue PGD.
Preventing genetic disease: PGD and prenatal testing
This study suggests that the apparent lack of research inter-
est in developing PGD clinically in the 1970s was due, at
least in part, to the parallel technological and clinical
development of prenatal testing in obstetric medicine.
Unlike PGD, prenatal testing did not require as-yet undevel-
oped single-cell testing techniques, but more significantly
did not entail the unfamiliar technological or ethical chal-
lenges of IVF. Rather, it involved the development of surgi-
cal gynaecological techniques that were more familiar to,
and so more readily accepted into, clinical practice.
Prenatal testing was initially performed by amniocente-
sis. Serr et al. (1955) first stained centrifuged amniotic fluid
cells for sex chromatin, karyotyping being used later (Steele
and Breg, 1966). The UK Abortion Act (1967) legalized ter-
mination of pregnancy on grounds of ‘substantial risk’ of
serious physical or mental handicap, allowing for clinical
intervention following amniocentesis. Indeed, the potential
to diagnose and terminate affected pregnancies played an
important role in the passage of the Abortion Act, many Par-
liamentarians emphasizing the ‘suffering caused to both
children and parents by such disasters’ (Jenkins: Hansard,
1966). The widespread public and professional attention
given to the thalidomide tragedy of the early 1960s ‘enabled
abortion to be formulated as a public health issue’ (Lee,
1998, p. 79), at a time when doctors felt that they had
‘failed to keep their contract’ if a baby was born as ‘any-
thing but normal’ (p. 167). Thus, at exactly the time that
proof of principle of PGD was demonstrated, the options
for prenatal testing were expanded.
Prenatal testing was taken up somewhat slowly in clinical
practice during the early 1970s (Figure 1; Milunsky, 1979,Figure 1 Plot of time course (by year) of PubMed search outcom
villus sampling (red line); ultrasound and prenatal diagnosis (green
(For interpretation of the references to colour in this figure legendp. 19), although the number of diagnosable conditions
increased steadily, and safety was demonstrated by
large-scale clinical trials conducted in America, Canada
and by the UK’s MRC (Milunsky, 1992, pp. 45–47). In addi-
tion, the experimental and clinical use of ultrasound in
gynaecological and obstetric practice rose steeply from
the early 1970s (Figure 1; White, 1982), making prenatal
testing safer still. In the early 1980s, chorionic villus sam-
pling (CVS) began to enter clinical practice (Christie and
Tansey, 2003, p. 46; Milunsky, 1992, p. 124), offering a
first-trimester alternative to later, and thus more physically
and emotionally traumatic, second-trimester amniocentesis
followed by abortion.
Despite the fact that prenatal testing was relatively new
to clinical practice, it was viewed more favourably than PGD
in the 1970s. For example, in their referees’ reports on
Edwards and Steptoe’s 1971 grant application to the MRC,
John Evans and Roger Short described PGD as ‘fanciful’
and ‘complicated and unnecessary’ and deemed amniocen-
tesis followed by abortion to be a ‘far simpler’ approach
(NA2). Indeed, the MRC, and much of the medico-scientific
community, had reservations about IVF in general and felt
that research on, or transfer of, IVF embryos would be
unethical until they were provided with ‘satisfactory evi-
dence that there would be no increased risk of abnormal
offspring’ (NA3). It was not until the birth of a healthy IVF
baby in 1978 that such attitudes towards IVF began to soften
(Johnson et al., 2010). The MRC declared the need for an
‘urgent’ review of policy on funding IVF research in
1978–1979 (NA4) and identified the investigation of ‘inher-
ited disease’ as one of the principal aims of embryo
research, encouraging the pursuit of ‘a screening device
for determining the chromosome constitution of an embryo’
(NA5). Moreover, key medico-scientific bodies suggested a
range of approaches to achieving PGD, including ‘the
removal of cells from the very early embryo’ (Royal Society,
1983) and ‘embryo division’ (RCOG, 1983). These bodies
submitted their views to the Government-sponsored Com-
mittee of Inquiry into Human Fertilisation and Embryology
(1982–1984; Warnock, 1984). Thus, from 1978 onwards,
members of a handful of key organizations expressed anes using, as search terms: amniocentesis (blue line); chorionic
line). Plots give an indication of the novelty of the technology.
, the reader is referred to the web version of this article.)
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disease, both by PGD and by other approaches. However,
as has been seen, it was not until 1986–1987 that this inter-
est was reflected in scientific meetings and active research.
Indeed, negative attitudes towards PGD persisted into
the early 1980s. For example, only two paragraphs among
the 79 pages of the Warnock Report (Warnock, 1984) were
devoted to PGD. These paragraphs were drafted by Anne
McLaren (Warnock, unpublished interview), who felt ‘dubi-
ous’ about the possibility of ‘wide scale’ social sexing,
and judged the detection of abnormalities by embryo biopsy
as ‘unlikely’ to become feasible ‘for some considerable
time’. Although described as a powerful advocate for
embryo research on the Warnock committee (secretary
Jenny Croft, unpublished interview), McLaren (1985) went
on to submit a pessimistic review article on PGD in July 1984
and published in the January/February 1985 edition of Pre-
natal Diagnosis. She concluded that PGD could ‘only be con-
sidered as a last resort’ as it would further decrease the
already very low success rate of IVF, and that CVS ‘would
seem to offer better prospects’. Although she discussed var-
ious approaches to PGD in humans and animal models,
McLaren deemed each to be fraught with difficulties: troph-
ectoderm biopsy was unlikely to succeed ‘within present
ethical constraints’; second polar body biopsy was ‘exact-
ing’ and provided only ‘limited’ information; nuclear trans-
plantation to provide biopsy material had been largely
‘unsuccessful’ in mouse models; and biopsy during cleavage
would require ‘much research’ to ensure that normal devel-
opment was not impeded.
Curiously, her perspective changed dramatically within
only a few months. Writing with WH Evans – one of
Edwards’ and Steptoe’s referees and thus another erstwhile
critic of PGD (NA2) – McLaren declared in Nature on 14
March 1985 that the ability ‘to circumvent the production
and transfer of severely genetically abnormal embryos’
was ‘almost within the grasp of medical science’ and the
‘means to undertake [it] just around the corner’ and
‘almost to hand’ (Evans and McLaren, 1985). McLaren’sTable 4 Key political events in the embryo research deba
Date Summary of main even
July 1984 Publication of the War
31 October 1984 Lords debate on the W
23 November 1984 Commons debate on th
27 November–29 December
1984
Contacts with MPs to e
5 December 1984 Unborn Children (Prote
15 January 1985 Pro-research all-party
15 February 1985 Second Reading Comm
March 1985 Voluntary Licensing Au
6–20 March 1985 Standing Committee D
3 May 1985 Report Stage debate o
7 June 1985 Commons MPs present
Powell Bill; Powell Bill
23 July 1985 Meeting of the pro-res
6 November 1985 CIBA Foundation meet
12 November 1985 Progress founded by penthusiasm for PGD was reiterated at a CIBA Foundation
meeting on human embryo research that she had organized
in November 1985 (some key participants listed in Table 3).
This meeting focused mainly on embryo research for infer-
tility treatment and contraceptive development and on
the ethico-legal aspects thereof (Bock and O’Connor, 1986).
PGD featured only briefly in a chapter on the diagnosis and
management of genetic disease and was described as a
technically difficult and unnecessary alternative to CVS
(Bock and O’Connor, 1986, p. 97). However, in the discus-
sion that followed (Bock and O’Connor, 1986, pp. 100–104),
Edwards and McLaren were both more positive about PGD,
while Modell deemed that it would be a ‘great benefit’ to
high-risk couples faced with the alternative of ‘stressful’
terminations. A later chapter (Bock and O’Connor, 1986,
p. 112) stressed the ‘real demand for diagnosis . . . during
the preimplantation stages’, and in its discussion Braude
(Bock and O’Connor, 1986, p. 115) was optimistic about
future prospects for PGD.
The pleas from Modell and others suggest that the
climate of medical opinion, propelled by patient pressure,
was shifting away from prenatal diagnosis, with its atten-
dant suffering, and was becoming more sympathetic
towards PGD (Christie and Tansey, 2003; Rapp, 1999;
Rothman, 1988, pp. 46–48). But was this transition driven
simply by a greater familiarity with, and less antipathy
towards, IVF? The final section in this paper suggests that
political debates in 1984 and 1985 provided a strong positive
stimulus for the proliferation of meetings and laboratory
studies on clinical PGD that ensued from 1986 onwards.
Gaining political credibility: PGD and the UK embryo
research debate
In the Parliamentary debates immediately following the
publication of the Warnock Report (19 July; Warnock,
1984), the majority of Lords (31 October 1984) and MPs
(23 November 1984) who spoke were firmly against human
embryo research (see Table 4 for key political dates). Thete, 1984–1985.
ts
nock Report
arnock Report
e Warnock Report
ncourage support for embryo research
ction) Bill tabled by Enoch Powell
discussion in the House of Commons
ons debate on the Powell Bill
thority formed by the MRC and RCOG
debates on the Powell Bill
n the Powell Bill
13 petitions with 4065 signatures against the
fails to secure extra time
earch Warnock Legislation Group
ing on embryo research
ro-research lobby members
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moral arguments, defining the ‘moral validity’ of embryo
research as dependent on the ‘nature of the human embryo
itself’ (Hansard, 1984a) and anti-research speakers rejected
the Warnock Report as ‘defective’ precisely because it
failed to ‘deal with the basic moral and ethical principle’
(Lord Rawlinson: Hansard, 1984a). Most speakers drew
strongly on anti-abortion rhetoric, arguing that embryo
research, like abortion, was ‘murder in a moral sense’ (Earl
of Halsbury: Hansard, 1984a). The Commons debate was
framed similarly (Abse: Hansard, 1984b). The Press picked
up on this parliamentary hostility (LSE1).
Alarmed by the anti-research rhetoric, scientists
responded. At the MRC, Joan Box sent a hastily drafted
memo (NA6) to Malcolm Godfrey (Second Secretary,
1983–1988):
1. Dawes’ Advisory Group [NA7] have prepared a draft
response [to the Warnock Report] indicating why research
is necessary and suggesting joint action with RCOG to
establish voluntary interim licensing arrangements – to
be considered by Council on 29th November . . .
3. After the Lords debate Professor Callum Macnaughton
(President of RCOG) concerned about the strength of
feeling expressed in debate, suggested to Dr Box that
he might approach you informally about a joint
initiative . . .
4. Several other scientists including Dr Whittingham, Dr
Lincoln, Dr Johnson and Dr Braude have expressed con-
cern that urgent action on the public relations front is
required – while public opinion is still being formed –
to modify the biased picture emerging from the media
and the Lords . . .
6. Norman Fowler [Secretary of State for Social Services,
1981–1987], worried about the pressure for a morato-
rium on research, is thought to be informing ministerial
colleagues that he will approach you and the RCOG about
the possibility of voluntary self-regulation being insti-
tuted urgently.
The memo continued by listing questions that had arisen,
including:
1. Should MRC public relations be high profile or low
profile?
2. Can scientists in the field proposing immediate action
such as contacting local MPs, writing to ‘The Times’,
speaking to the Press, etc meanwhile be reassured that
you are happy that they do this in an individual
capacity . . .?
The reply on 7 November 1984 (NA8) indicates that the
memo had been discussed with Sir James Gowans (Secretary
of the MRC) and confirmed that he was taking forward dis-
cussions on what would later become the Voluntary Licens-
ing Authority (BL3), advised a low profile for the MRC and
said that ‘Sir James would not wish to take any initiative
about encouraging people to write to ‘‘The Times’’, etc.’
Notwithstanding this last point, those who would be most
adversely affected by a ban on research were already
active. For example, earlier in 1984, Peter Braude (clini-
cian), Martin Johnson and Hester Pratt (scientists) at theUniversity of Cambridge had embarked on a 5-year
programme of research on human and animal embryos
funded by the UK Medical Research Council (MRC Annual
Report for 1983/4), much of which risked becoming prohib-
ited. During November and December 1984, they initiated a
pro-embryo research campaign, contacting MPs (listed in
LSE2) and contributing letters and articles in the media
(LSE3).
On 5 December of that year, Ulster Unionist MP Enoch
Powell introduced a Private Members’ Bill to ban all produc-
tion and use of human embryos, other than to help an infer-
tile woman to become pregnant. This galvanized further
campaigning, such that Braude and his colleagues expanded
their media activities (LSE4), contacted Government minis-
ters and the cabinet office (LSE5) and organized an ‘all party
discussion on embryo research in the House of Commons’
(15 January, LSE6). They joined forces with Joanna Cham-
bers, the General Secretary of the Birth Control Campaign,
a lobbying group with well-established political contacts
(LSE7), and the Women’s Reproductive Rights Centre
(LSE8). Despite their efforts and a letter from Gowans to
The Times on the eve of the debate (LSE9), the Bill received
a large Commons majority of 238:66 at its second reading on
15 February 1985 (Hansard, 1985). Shortly thereafter,
Braude and Johnson (LSE10) wrote to Macnaughton and
Gowans (copied to McLaren and David Whittingham, both
heads of MRC Units), asking for more direct administrative
support for the campaigning. The MRC, which in January
1985 had issued a revised policy statement on Research
Related to Human Fertilisation and Embryology (LSE11,
1985), responded by assigning Dr Keith Gibson to help with
the lobbying (LSE12). The group of scientists actively lobby-
ing Parliament by now included Macnaughton, McLaren,
Whittingham and Robert Winston (LSE13).
Mulkay (1997, p. 63) suggests that ‘in these early
debates, reference to control of genetic disease had been
a minor feature’ and that only ‘during later pro-research
speeches’ did it become ‘the central topic’. However, a
close examination of the February Commons debate on
the Powell Bill (Hansard, 1985) reveals that all but one of
11 pro-research speakers referred to control of genetic dis-
ease, both by PGD and other approaches, while 10 of the 13
anti-research MPs responded to such claims. This was the
result of the briefings that emphasized the potential clinical
benefits of PGD by ‘embryo biopsy’ provided to pro-research
Parliamentarians, including Leo Abse, David Crouch, Frank
Dobson, Willie Hamilton, Jo Richardson, Peter Thurnham
and Daffyd Wigley (CC1; Hansard, 1985).
However, the issue of PGD proved divisive amongst
anti-research speakers in the Commons debate on the Pow-
ell Bill. Some disagreed with PGD in principle and argued
that, in caring for handicapped children, ‘individuals and
the community’ were made ‘that much greater’ (Beith:
Hansard, 1985). However, most did not oppose the principle
of handicap prevention, just the use and destruction of
embryos to achieve it, equating the embryo with an ‘unborn
child’ and so claiming that the potential benefits to ‘other
human beings’ (Winterton: Hansard, 1985) could never be
justified. Others were concerned that the ‘rectification of
genetic defects’ taken to ‘its logical conclusion’, selection
for characteristics such as IQ and skin colour would follow,
such that prospective parents could ‘book’ a ‘tall, dark,
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bell-Savours: Hansard, 1985). Still others doubted that
embryo research could in fact lead to clinical PGD (Braine:
Hansard, 1985) and suggested that research on human
gametes and animal embryos would be more fruitful and
more ethical (Tracey: Hansard, 1985). Six anti-research
speakers supported this stance by citing the highly-
publicized views of pro-life French geneticist Jerome
Lejeune (21 February; Walgate, 1985). Lejeune had flown
in from Paris to address the MPs (Braine: Hansard, 1985)
and had claimed that PGD could not work, a claim later
challenged in a letter to The Times by eight leading genet-
icists (Bobrow et al., 1985).
Powell himself took a somewhat different stance to many
anti-research speakers, treading a fine line between endors-
ing IVF and PGD whilst opposing destructive research.
Although he was one of only three anti-research speakers in
the February Commons debate who did not refer directly to
the control of genetic disease, his subsequent private and
public communications emphasized his strong desire that
the Bill should allow ‘embryo biopsy’ (CC1) to diagnose and
exclude abnormal embryos. If, according to Powell, there
was ‘a clinical ethical duty not to insert an unsatisfactory
embryo’, then ‘there must be a right (or duty) within the Bill’
to allow tests ‘to detect unsatisfactory embryos’ (CC2). Pow-
ell asserted that such tests would only be precluded ‘if they
required the creation and use of IVF embryos solely for the
purposes of research’, rather than transfer (CC3). As such,
his view was in diametric opposition to that of the Warnock
Report (1984), which stated ‘no embryo which has been used
for research should be transferred to a woman’.
In March 1985, Powell sought advice on the impact of his
Bill on PGD from Roy Cunningham, Assistant Secretary at the
Department of Health, who later was to lead the team of
policy officials involved in drafting the HFE Bill (Anon, 2008;
Cunningham, 1991). Cunningham confirmed: ‘the [Powell]
Bill as it stands would allow such procedures [biopsy]’ (CC4).
Later that month, however, Cunningham warned Powell
that the achievement of clinical PGD would first ‘depend
on further research’, which might fall outside the limits of
the Bill (CC2). By then, however, Powell had already
announced to the Parliamentary Standing Committee that
he had been ‘assured in writing’ that ‘embryonic biopsy
could continue’ under his Bill (CC1).
Powell’s stance on PGD fractured the anti-research cam-
paigners. The Order of Christian Unity warned that the Bill
would ‘not achieve effective protection for the human
embryo’ (CC5), while David Poole, chairman of the Associa-
tion of Lawyers for the Defence of the Unborn, could ‘no
longer support’ or ‘even conceal [his] opposition’ to the Bill,
as it would allow embryos with ‘genetic imperfection’ to be
‘discarded and destroyed’ (CC6). In addition, although Pow-
ell was the only speaker in the Standing Committee debate
in March to stress that PGD would be allowed under his Bill,
some of his closest colleagues subsequently echoed his
stance. For example, Bernard Braine, in a letter to geneti-
cist Martin Bobrow, confirmed that ‘there is nothing in
the . . . Bill to stop embryonic biopsy’, but somewhat incon-
gruously stated in the same paragraph that ‘there is no way’
that the ‘destruction of the [diagnosed] embryo could be
described as a ‘cure’’, perhaps indicating his own ambiva-
lence towards PGD (CC7).Powell’s stance, and its impact on his allies, alerted
pro-research Parliamentarians and lobbyists to a potential
weakness in the anti-research case. They accused him of
being ‘totally disingenuous’ and maintained that destructive
embryo research was ‘essential’ before PGD ‘could ethically
be used in a clinical context’ (Hamilton, CC1). Indeed, MP
Peter Thurnham wrote at least three letters over the next
2 years to Powell and Phyllis Bowman of the Society for
the Protection of the Unborn (SPUC), challenging Powell’s
claim to the Standing Committee that the Bill would ‘in no
way interfere with the practice of IVF procedures’ or their
‘improvement’ (CC8). The potential benefits of PGD also
appeared to play well with the public and may have further
stimulated the pro-research lobby to doggedly pursue the
issue. Thus, in April 1985, a Marplan poll commissioned by
Middlesex Polytechnic reported that ‘nearly half of the
opponents [of embryo research] changed their mind when
asked if they would favour research if it would help elimi-
nate genetic diseases’, shifting the totals in support of such
research from 32 to 51% (Clarke, 1985). Articles appeared in
the Press by, or quoting, eminent geneticists describing the
potential of PGD (LSE14).
The response of the anti-research lobby, including Pow-
ell, was to demand that the scientists ‘provide detailed
information of research projects (particularly those relating
to genetic diseases)’ which would be precluded by the Bill,
but, according to the All-Party Parliamentary Pro-Life Group
in a letter to The Times, they received only ‘vague conjec-
tures’ (CC9). Indeed, in a Nature editorial in March 1985,
the scientists were advised that they could ‘help themselves
and even help defeat the bill’ by publishing their embryo
research proposals (Anon, 1985). At a rally of the SPUC 4
months later, Powell demanded that ‘the government and
the professions must come clean with the public’ and
painted the parents of genetically handicapped children as
gullible, having displayed ‘their private griefs in lieu of log-
ical argument’ (CC10). Might it have been these direct chal-
lenges to scientists that provided the motivation for them to
engage intellectually and practically with PGD?
Notwithstanding these challenges, by November 1985,
when the pro-research lobby had consolidated formally into
the campaign group Progress, it identified from the outset
the ‘prevention of . . . congenital handicap’ as one of three
main objectives of embryo research (LSE7) and received
strong support from numerous disability charities, including
MIND, SENSE and MENCAP (LSE11; Rix et al., 1985). Indeed,
Progress increasingly emphasized PGD in their lobbying,
such that by January 1988 in a brief distributed to all MPs,
Progress devoted only five lines to IVF treatment but 28
lines to ‘preventing handicap’ (LSE13).
This political focus on PGD was reinforced by the concur-
rent discussions on termination of pregnancy. In the 1980s,
abortion was debated in parallel with embryo research, as
Parliament considered whether to reduce the time limit of
legal terminations from 28 weeks of pregnancy to 18, 20,
22, 24 or 26 weeks. Parliamentarians on both sides centred
their case on late abortions performed on grounds of fetal
abnormality. Anti-abortion speakers suggested that ultra-
sound and CVS could allow diagnosis as early as 9–10 weeks
(Lord Bishop of Birmingham: Hansard, 1987), obviating the
need for late abortions following amniocentesis. In
contrast, those against reducing the legal time limit argued
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had not been confirmed (Newton: Hansard, 1988a). They
maintained that, ‘although few in number’, those late abor-
tions following amniocentesis were ‘important because a
severely handicapped child can cause immense personal
and domestic problems’ (Lord Butterworth: Hansard,
1988b). Crucially, several pro-research Parliamentarians
highlighted the potential for PGD to provide an alternative,
emphasizing the ‘illogicality of some Honourable Members’
who supported reducing the legal time limits, ‘but at the
same time’ opposed the research that would ‘prevent the
necessity for late abortions’ (Rhodes James: Hansard,
1988c). In doing so, the potential clinical benefits of PGD
were re-iterated, gaining further political credibility.Discussion
This article has traced the history of the development of
PGD from initial animal studies in the late 1960s to its clin-
ical application in 1990. It has found that both its develop-
ment and application in humans is partially explicable
through the technological difficulties posed by species dif-
ferences, limited human embryo availability and the
requirement for sensitive tests. However, these difficulties
alone do not adequately explain the patterns of activity
observed. Attempts were made to overcome the technical
hurdles in farm animals in the 1970s and early 1980s, but
not in humans, suggesting a lack of motivation to achieve
PGD clinically. The evidence suggests that through the
1970s this lack of interest may have been due to the parallel
development and application of clinical prenatal diagnostic
technologies. These were technically and conceptually
more familiar to clinicians than IVF and embryo research,
both of which generated strong medico-scientific reserva-
tions (Johnson et al., 2010). However, by the mid-1980s,
IVF babies were being born in increasing numbers (HFEA,
2010) and in several countries (Cohen et al., 2005), and
IVF itself had gained greater acceptance both publicly and
professionally – as shown in the MRC’s 1982 decision to fund
research into IVF (Johnson et al., 2010). Indeed Powell him-
self, like many of his politically aligned colleagues, sup-
ported IVF as a treatment for the infertile.
However, changing attitudes to IVF do not in themselves
explain why interest in pursuing PGD took off only from
1986. The motivation to work on this technique seems
unlikely to have come from the work on large farm animals
because, whilst almost all of the later experimental studies
cited Gardner and Edwards’ 1968 paper, almost none cited
the intervening farm animal work despite obvious concep-
tual and methodological similarities. Likewise, the advent
of the PCR technique seems an unlikely, if much touted,
stimulus. Thus, although the first paper applying PCR was
published in December 1985 (Saiki et al., 1985), it reported
use of template DNA from the equivalent of 600 diploid
genomes. A paper in November 1986 lowered this figure to
150 nuclei (Saiki et al., 1986), but it was another year
before the detailed method was published (Mullis and Falo-
ona, 1987) and 2 years before single cell PCR was reported
(Li et al., 1988). Perhaps not surprisingly, therefore, this
methodology seemed to percolate only gradually into the
collective consciousness of those discussing PGD duringthe 1986 CIBA and ESHRE meetings, and even then as one
of several possibilities under consideration (Edwards, 1987).
So, whilst it is undoubtedly the case that technological lim-
itations posed difficulties from the late 1960s to the
mid-1980s, and that possible technical solutions began to
emerge in the late 1980s, the collective interest in PGD
was already evident before this happened. This change in
interest was most vividly demonstrated, and pinned in time
to early 1985, in the publications of McLaren, when she
transformed from a PGD sceptic to PGD enthusiast. She
did so at exactly the time that the hostile Parliamentary
responses to the Warnock report and the Powell Bill were
threatening medical research. Powell did not want to stop
IVF as a treatment for the infertile: it was the use of
embryos in research to which he objected as being both
unethical and unnecessary. This objection to research pro-
vided the focus around which a coalition of supporters rap-
idly formed to generate a powerful Parliamentary
opposition, who, like Powell, appeared impervious to the
fact that IVF was based on human embryo research.
McLaren’s response was important, because she was
influentially placed. She had been a member of the War-
nock Committee and was a respected player in the MRC
and Royal College of Obstetricians and Gynaecologists
(RCOG). She was also an articulate public defender of
embryo research and PGD, for example by publishing in
Nature, a science journal calculated to command a much
wider audience than the esoteric journals used by those
working on large farm animals. She was also prepared to
talk to the opposition, having lectured on the status of
the human embryo at the September 1984 AGM of LIFE,
an anti-abortion organization (Bl3). However, she was
not alone. The archival evidence shows the depth of con-
cern generated in the scientific community by the Parlia-
mentary reactions to human embryo research.
Significantly, this concern was not limited to the small
group of scientists directly concerned with embryo
research, but was also evident in the higher echelons of
the MRC and the RCOG. From this concern, a pro-research
lobby alliance was hastily assembled, initially composed of
scientists, doctors and MPs, but soon attracting medical
charities, patients and pro-choice women’s groups.
The Parliamentary response threatened the develop-
ment of IVF as a safe medical technology, based on the
moral case made by opponents of human embryo research.
PGD emerged as a strategic weapon with the potential
strength to divide and defeat this opposition. The evidence
illustrates the fracture lines that PGD opened within the
opposition, alienating Powell from some of his key support-
ers. Whilst this paper agrees with Mulkay that PGD acquired
ever greater political importance as the debate wore on,
such that by 1989, 75% of pro-research Lords speakers made
significant reference to the regulation of genetic disease,
compared with only 50% to infertility treatment (Mulkay,
1997, p. 187), it differs from him in the finding that this
political focus was evident from the outset and in the direct
challenges that each side levelled at their opponents. Cru-
cially, the challenge by Powell to prove that research was
required for PGD to be developed preceded the pivotal
clinically oriented PGD interest of 1986–1987, and, it is
suggested here, stimulated it. Indeed, as has been seen,
key members of the pro-research lobby subsequently
468 AA Theodosiou, MH Johnsonparticipated in the ESHRE and CIBA meetings on PGD and
many were involved in laboratory investigations on PGD in
the late 1980s (Table 3). Such key players were then, as a
direct result of their lobbying experience and contacts, well
placed to communicate their research progress to both pub-
lic and parliamentarians between 1985 and 1990, reaffirm-
ing the political focus on PGD. Several also recognized the
need to ‘get together to influence the European Parliament’
in order to prevent a pan-European wave of human embryo
research prohibition, stressing that the ‘overwhelming clin-
ical need to do something to help families at high genetic
risk’ using PGD should be emphasized politically throughout
Europe (Penketh cited in Anon, 1987). Unsurprisingly, how-
ever, the argument that PGD offered moral advantages over
later abortion had less force in Catholic Europe than in the
UK (Anon, 1987), which was therefore strongly placed both
ethically and practically to develop PGD through to clinical
application.
In conclusion, this paper argues that, whilst the concept
of PGD did indeed shape the course and outcome of Parlia-
mentary debates leading to the HFE Act of 1990, those
debates themselves exerted a powerful stimulus to the
development of PGD as a novel technology. The scientific
community perhaps should acknowledge a debt to Powell
for his positive influence on the emergence of this new med-
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